The effects of different dosage levels of hepatitis B vaccine as booster on anti-HBs-negative children 5–15 y after primary immunization; China, 2009–2010

Figures & data

Table 1. Characteristics of the study subjects

Age group (Years)	Number of cases	Male		Female		Age (‾x ± s, years)
		Cases (N)	Rate (%)	Cases (N)	Rate (%)
Received hepB booster vaccination with 5 ug
5–	458	225	49.1	233	50.9	7.8 ± 1.5
10–15	518	248	47.9	270	52.1	12.5 ± 1.3
Received hepB booster vaccination with 10 ug
5–	506	266	52.6	240	47.4	7.9 ± 1.3
10–15	624	318	51.0	306	49.0	12.4 ± 1.4

Table 2. Distribution of age-specific anti-HBs titers before booster vaccination

Sex	Age group (Years)	Dosage	Number of cases	anti-HBs titer (0–1 mIu/ml)		anti-HBs titer (1–10 mIu/ml)		χ^2	P value
				Cases (N)	Rate (%)	Cases (N)	Rate (%)
Male	5–	5 μg	225	80	35.6	145	64.4	0.407	>0.05
		10 μg	266	102	38.3	164	61.7
	10–15	5 μg	248	121	48.8	127	51.2	0.082	>0.05
		10 μg	318	159	50.0	159	50.0
Female	5–	5 μg	233	88	37.8	145	62.2	0.190	>0.05
		10 μg	240	86	35.8	154	64.2
	10–15	5 μg	270	134	49.6	136	50.4	0.231	>0.05
		10 μg	306	158	51.6	148	48.4
Total	5–	5 μg	458	168	36.7	290	63.3	0.023	>0.05
		10 μg	506	188	37.2	318	62.9
	10–15	5 μg	518	255	49.2	263	50.8	0.280	>0.05
		10 μg	624	317	50.8	307	49.2

Table 3. Antibody seroconversion rates and GMTs after the different-dosage hepatitis B vaccine booster vaccination

Sex	Age group (Years)	Dosage	Number of cases	After the first booster vaccination			After the third booster vaccination			χ ^2 ^*	P value*	Z**	P value**
				Positive cases (N)	Positive Rate (%)	GMTs (‾x ± s, mIu/ml)	Positive cases (N)	Positive Rate (%)	GMTs (‾x ± s, mIu/ml)
Male	5–	5 μg	225	217	96.4	626 ± 4	225	100.0	786 ± 3	_	<0.05	−2.437	<0.05
		10 μg	266	258	97.0	2002 ± 5	266	100.0	2847 ± 3	_	<0.05	−4.633	<0.05
	10–15	5 μg	248	209	84.3	267 ± 5	246	99.2	620 ± 4	35.027	<0.05	−9.529	<0.05
		10 μg	318	289	90.9	972 ± 7	318	100.0	2644 ± 3	27.034	<0.05	−11.391	<0.05
	5–15	5 μg	473	426	90.1	686 ± 5	471	99.6	669 ± 3	43.022	<0.05	−9.037	<0.05
		10 μg	584	547	93.7	2205 ± 5	584	100.0	2841 ± 3	35.027	<0.05	−11.995	<0.05
Female	5–	5 μg	233	215	92.3	358 ± 5	232	99.6	644 ± 4	_	<0.05	−0.939	>0.05
		10 μg	240	231	96.3	907 ± 6	240	100.0	2339 ± 4	_	<0.05	−2.948	<0.05
	10–15	5 μg	270	240	88.9	655 ± 5	269	99.6	724 ± 3	27.034	<0.05	−7.849	<0.05
		10 μg	306	280	91.5	2095 ± 5	303	99.0	2844 ± 3	_	<0.05	−10.686	<0.05
	5–15	5 μg	503	455	90.5	312 ± 5	501	99.6	632 ± 4	42.188	<0.05	−6.644	<0.05
		10 μg	546	511	93.6	939 ± 6	543	99.5	2490 ± 3	28.265	<0.05	−10.375	<0.05
Total	5–	5 μg	458	432	94.3	463 ± 8	457	99.8	717 ± 3	21.333	<0.05	−2.317	>0.05
		10 μg	506	489	96.6	1675 ± 6	506	100.0	2844 ± 3	_	<0.05	−5.393	<0.05
	10–15	5 μg	518	449	86.7	150 ± 22	515	99.4	610 ± 2	64.015	<0.05	−12.410	<0.05
		10 μg	624	569	91.2	519 ± 14	621	99.5	2415 ± 4	48.176	<0.05	−15.580	<0.05
	5–15	5 μg	976	881	90.3	255 ± 11	972	99.6	658 ± 4	87.097	<0.05	−11.060	<0.05
		10 μg	1130	1058	93.6	877 ± 11	1127	99.7	2599 ± 3	65.127	<0.05	−15.858	<0.05

*McNemar test,“—”is Exact test; **Wilcoxon signed–rank test.

Figure 1. Flow chart of the participants enrolled in the study. A total of 3818 children born between 1993 and 2003 with three-dose Hepatitis B vaccine were reviewed. Of the 3818 children, 1712 children were excluded. Thus, 2106 children were included and were vaccinated with HepB in the study.

Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97 - 107; http://dx.doi.org/10.1046/j.1365-2893.2003.00487.x; PMID: 14996343

 PubMed Web of Science ®Google Scholar